Application of the ESMO Magnitude of Clinical Benefit Scale to assess the clinical benefit of antibody drug conjugates in solid cancer: a systematic descriptive analysis of phase III and pivotal phase II trials
Objective The aim of this study was to assess the clinical benefit value of approved antibody drug conjugates (ADCs) for solid tumours using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) V.1.1.Design Systematic descriptive analysis.Data sources PubMed was...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-06-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/14/6/e077108.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|